Merger Play - 500 Beiträge pro Seite
eröffnet am 10.10.07 15:14:04 von
neuester Beitrag 10.10.07 21:39:21 von
neuester Beitrag 10.10.07 21:39:21 von
Beiträge: 53
ID: 1.133.798
ID: 1.133.798
Aufrufe heute: 0
Gesamt: 5.524
Gesamt: 5.524
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| heute 20:17 | 3143 | |
| vor 39 Minuten | 2978 | |
| heute 17:59 | 2538 | |
| heute 11:52 | 2521 | |
| 08.05.24, 11:56 | 2440 | |
| vor 22 Minuten | 2036 | |
| heute 20:55 | 1717 | |
| heute 20:23 | 1589 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.772,85 | +0,46 | 131 | |||
| 2. | 3. | 0,2170 | +3,33 | 125 | |||
| 3. | Neu! | 8,8800 | +57,45 | 108 | |||
| 4. | 4. | 168,47 | -2,04 | 103 | |||
| 5. | 14. | 5,7540 | -2,18 | 56 | |||
| 6. | 2. | 0,2980 | -3,87 | 50 | |||
| 7. | 5. | 2,5600 | -6,91 | 49 | |||
| 8. | 7. | 6,8000 | +2,38 | 38 |
Feedback
Wahnsinn, warum kriegt man hier keine Stücke mehr ??? Pennt der Makler in Frankfurt 
Seit einer halben Stunde versuch dort schon stücke zu kriegen mit Limit 6, 7 oder 8 cent es tut sich gar nichts Bid Ask immer noch beim Alten 0,03 zu 0,031
Was kann man da machen
Was kann man da machen
Antwort auf Beitrag Nr.: 31.925.677 von Kaufmonster am 10.10.07 15:19:03Versuchs mit 10 drüben ist schon 0,13.
Gruß SGDfigther
Gruß SGDfigther
Das ist es ja, nicht mal die Taxe ändert sich, Sauere was da wieder abgeht.......
Antwort auf Beitrag Nr.: 31.925.677 von Kaufmonster am 10.10.07 15:19:03bei mir ist kein ask mehr dirn!??! aktualisiere mal
Trading Spotlight
Der kann mich jetzt mal, ich wollte schon rein als in USA Taxe bei 5 Cent stand, jetzt nicht mehr
Antwort auf Beitrag Nr.: 31.925.901 von Kaufmonster am 10.10.07 15:31:19Jetzt haste dem teufelsmakler aber gezeigt wo der schwefel hängt......
Versucht soch mal in Berlin zu handeln!
Antwort auf Beitrag Nr.: 31.927.503 von Gommez am 10.10.07 16:56:58Jetzt ist doch bid und ask da. 14/18 in Frankfurt.
Ich trau mich aber nicht rein.
Gruß SGDfigther
Ich trau mich aber nicht rein.
Gruß SGDfigther
Antwort auf Beitrag Nr.: 31.927.691 von SGDfigther am 10.10.07 17:07:32ich hab schon merhmals versucht ins ask zu kaufen, jedesmal taxt der penner dann hoch...
was ist denn ein Merger Play?
Sollte man die jetzt noch halten oder Gewinne einfahren?
Sollte man die jetzt noch halten oder Gewinne einfahren?
Leute vergesst es, der zeitpunkt ist entscheidend und ich hab heut nachmittag auf OTCBB-Alert 5 Minuten nach Erscheinen der Merger-Meldung versucht hier rein zu kommen - never nichts, jetzt kann mich das Teil mal, ist grossteils gelaufen 
Der Makler hat sie definitiv nicht mehr alle so viel steht fest, es wären genug Stücke da gewesen, aber wer nicht will der hat schon.........Bis zur nächsten Chance
Der Makler hat sie definitiv nicht mehr alle so viel steht fest, es wären genug Stücke da gewesen, aber wer nicht will der hat schon.........Bis zur nächsten Chance
RT CHART USA bitte vielleicht kaufe ich in usa Live Chart wäre super?
Unglaublich. Kann einer mal einen chart mit Volumen bitte reinstellen? Ich hab zwar Rt, kanns aber leider nicht reinstellen.
Danke
Danke
RT chart steht in denn ersten nachrichten
Bald 1000% und keiner bekommts mit.
hab mir in usa einige gekauft
1000 Stück zu 0,22 in Frankfurt.
Hab aber wieder kein bid/ask
Gruß SGDfigther
Hab aber wieder kein bid/ask
Gruß SGDfigther
Moin Mädels,
war das ein Stress reinzukommen
war das ein Stress reinzukommen
Antwort auf Beitrag Nr.: 31.928.324 von SGDfigther am 10.10.07 17:48:13habe erst auch versucht in FFM zu 6 rein,
der Makler gibt da echt nix ab, bin dann in usa rein
der Makler gibt da echt nix ab, bin dann in usa rein
Antwort auf Beitrag Nr.: 31.928.357 von axcol am 10.10.07 17:50:27Waren das deine 1000 in Frankfurt
hot hot hot
danke dir axol
lg speku
danke dir axol
lg speku
Antwort auf Beitrag Nr.: 31.928.415 von SGDfigther am 10.10.07 17:53:52Also ich spiele schon in einer anderen liga
lauter harte Zocker hier, fehlt noch Aloe
Antwort auf Beitrag Nr.: 31.928.516 von axcol am 10.10.07 17:59:06was ist denn hier los
und da bin ich schon
und da bin ich schon
Antwort auf Beitrag Nr.: 31.928.545 von aloevera2750 am 10.10.07 18:01:04Wenn man vom Teufel spricht
wo will die hin RT USA0,38
Hat denn keiner mal einen Rt chart? Mit Volumen, meine ich. Rt hab ich selber.
Habt ihr eigentlich schon das hier gesehen? 
Short
Interest
16,564.000
http://www.bloomberg.com/apps/quote?ticker=potp
Short
Interest
16,564.000
http://www.bloomberg.com/apps/quote?ticker=potp
Antwort auf Beitrag Nr.: 31.928.843 von strongbuyamitelo am 10.10.07 18:19:34
Antwort auf Beitrag Nr.: 31.928.909 von aloevera2750 am 10.10.07 18:23:51
okidoki bin raus Mädels 
hat sich echt gelohnt von 0.12 auf 0.37 gerne wieder
Kann mir nun jemand erklären was ein Merger Play ist?
hat sich echt gelohnt von 0.12 auf 0.37 gerne wieder
Kann mir nun jemand erklären was ein Merger Play ist?
woooow...hätte ich das mal vorher gewusst....wie seit ihr darauf gestoßen?
Antwort auf Beitrag Nr.: 31.929.169 von JimBob23 am 10.10.07 18:40:52grob erklärt:
Popt wird übernommen
Popt wird übernommen
hier gwehts ja ab Glückwunsch @ all Investierten
Glückwunsch @ all Investierten
Antwort auf Beitrag Nr.: 31.929.227 von axcol am 10.10.07 18:44:45thx aber von wem + für wieviel?
Muss ich mich da wieder reinkaufen?
Muss ich mich da wieder reinkaufen?
Antwort auf Beitrag Nr.: 31.929.282 von Wehlofant am 10.10.07 18:48:56
Antwort auf Beitrag Nr.: 31.929.838 von aloevera2750 am 10.10.07 19:20:37
Press Release Source: Point Therapeutics, Inc.
DARA BioSciences and Point Therapeutics Announce Merger Plans
Wednesday October 10, 8:00 am ET
RALEIGH, N.C. & WELLESLEY HILLS, Mass.--(BUSINESS WIRE)--DARA BioSciences(TM), a privately held development-stage pharmaceutical company, and Point Therapeutics, Inc. (NASDAQ: POTP - News), a biopharmaceutical company, today announced that they have entered into a definitive agreement to merge.
ADVERTISEMENT
Pursuant to the merger agreement, DARA will merge with a subsidiary of Point, with DARA surviving as a wholly-owned subsidiary of Point. After giving effect to the merger, DARA stockholders will hold 96.4% of Point's outstanding shares of common stock on a fully-diluted basis, and Point will change its name to DARA BioSciences, Inc. and be based in Raleigh. The acquisition is intended to be a tax-free reorganization under Section 368(a) of the Internal Revenue Code and is expected to close in the first quarter of 2008.
The combined company plans to evaluate and prioritize its potential research and development programs. DARA and Point's combined R&D assets for the development of therapeutics are focused in the areas of metabolic diseases, including Type 2 diabetes, neuropathic pain, dermatologic disorders, and oncology. A recently signed license agreement with Bayer Pharmaceuticals grants DARA exclusive worldwide rights to a series of patents and compounds for the treatment of metabolic diseases, including Type 2 diabetes and dyslipidemia, expanding DARA's current product candidate pipeline for metabolic diseases. DARA is also developing a novel therapeutic candidate for the treatment of chronic neuropathic pain in cancer patients, a program that is currently in a Phase 2 clinical trial.
Commenting on the announced merger plans, Richard A. Franco, Sr., DARA's President and Chief Executive Officer, stated, "All parties involved believe this to be a logical and productive course of action given the potential synergies of combining Point and DARA. We believe this transaction provides an exciting opportunity for the stockholders of both companies to realize value and liquidity from this combination."
"We are excited about the opportunity to merge with DARA," said Don Kiepert, Point's Chairman and President. "The combination of Point and DARA will give our stockholders an opportunity to retain an equity interest in a stronger company with a broad and attractive portfolio of potential products."
Point and DARA believe that the proposed merger will qualify as a "reverse merger" under NASDAQ Marketplace Rule 4340. As a result, although Point's common stock is currently listed on NASDAQ, DARA intends to file an initial listing application and satisfy all requirements for initial listing, subject to the completion of the merger and NASDAQ approval. As previously announced on September 17, 2007, Point received a determination letter from the staff of The NASDAQ Stock Market indicating that Point's securities are subject to potential delisting from NASDAQ. The staff determination was based on the fact that Point does not currently meet the $1 minimum share price requirement for continued listing on NASDAQ and that Point's recent cessation of its clinical and research operations renders Point a "public shell," or non-operating company in the opinion of the staff. Point has requested a hearing before a NASDAQ Listing Qualifications Panel and intends to seek continued listing of its common stock pending the completion of the merger, subject to NASDAQ approval.
About Point Therapeutics, Inc.
Point Therapeutics, Inc. is a biopharmaceutical company which has studied its lead product candidate, talabostat, in a number of human clinical trials in late-stage cancers. Recent interim clinical results caused Point's Independent Data Monitoring Committee to recommend stopping Point's most advanced clinical trials, two Phase 3 talabostat studies for patients in advanced non-small cell lung cancer. Subsequently, the talabostat clinical development program was put on clinical hold by the FDA. Point has also studied talabostat in several Phase 2 trials, including as a single-agent and in combination with cisplatin in metastatic melanoma, in combination with rituximab in advanced chronic lymphocytic leukemia, and in combination with gemcitabine in Stage IV pancreatic cancer. Due to cash limitations, Point is not currently funding any research or clinical operations.
About DARA BioSciences, Inc.
DARA BioSciences(TM), Inc. is a Raleigh, North Carolina-based development-stage pharmaceutical company that acquires promising therapeutic molecules and medical technologies directly. DARA focuses its therapeutic development efforts on small molecules from late preclinical development through phase 2 clinical trials. DARA is developing a portfolio of therapeutic candidates for neuropathic pain, metabolic diseases including Type 2 diabetes, and dermatological disorders.
For more information, please contact DARA at 919-872-5578 or visit our web site at www.darabiosciences.com.
Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include receipt of stockholder and regulatory approvals and other risks that the transaction might not close, integration of the two companies, risks related to the potential lack of a liquid market for the company's stock, reliance on key employees, risks of testing of drug candidates for proof of principle, risks of regulatory review and clinical trials, competition, market acceptance for approved products, if any, and intellectual property risks.
Additional Information
In connection with the merger between DARA and Point, Point intends to file with the SEC a registration statement on Form S-4, containing a joint proxy statement/prospectus and other relevant materials. INVESTORS AND SECURITY HOLDERS OF DARA AND POINT ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND THE OTHER RELEVANT MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT DARA, POINT AND THE MERGER. The joint proxy statement/prospectus and other relevant materials (when they become available), and any other documents filed by Point with the SEC, may be obtained free of charge at the SEC's web site at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents (when they are available) filed with the SEC by Point by directing a request to: Point Therapeutics, Inc., 70 Walnut Street, Wellesley Hills, MA 02481, Attention: Investor Relations.
Point and its executive officers and directors may be deemed to be participants in the solicitation of proxies from the stockholders of Point in favor of the merger. Information about the executive officers and directors of Point and their ownership of Point common stock is set forth in Point's Annual Report on Form 10-K/A filed with the SEC on April 30, 2007. Investors and stockholders may obtain more detailed information regarding the direct and indirect interests of DARA, Point and their respective executive officers and directors in the merger by reading the joint proxy statement/prospectus regarding the merger when it becomes available.
Press Release Source: Point Therapeutics, Inc.
DARA BioSciences and Point Therapeutics Announce Merger Plans
Wednesday October 10, 8:00 am ET
RALEIGH, N.C. & WELLESLEY HILLS, Mass.--(BUSINESS WIRE)--DARA BioSciences(TM), a privately held development-stage pharmaceutical company, and Point Therapeutics, Inc. (NASDAQ: POTP - News), a biopharmaceutical company, today announced that they have entered into a definitive agreement to merge.
ADVERTISEMENT
Pursuant to the merger agreement, DARA will merge with a subsidiary of Point, with DARA surviving as a wholly-owned subsidiary of Point. After giving effect to the merger, DARA stockholders will hold 96.4% of Point's outstanding shares of common stock on a fully-diluted basis, and Point will change its name to DARA BioSciences, Inc. and be based in Raleigh. The acquisition is intended to be a tax-free reorganization under Section 368(a) of the Internal Revenue Code and is expected to close in the first quarter of 2008.
The combined company plans to evaluate and prioritize its potential research and development programs. DARA and Point's combined R&D assets for the development of therapeutics are focused in the areas of metabolic diseases, including Type 2 diabetes, neuropathic pain, dermatologic disorders, and oncology. A recently signed license agreement with Bayer Pharmaceuticals grants DARA exclusive worldwide rights to a series of patents and compounds for the treatment of metabolic diseases, including Type 2 diabetes and dyslipidemia, expanding DARA's current product candidate pipeline for metabolic diseases. DARA is also developing a novel therapeutic candidate for the treatment of chronic neuropathic pain in cancer patients, a program that is currently in a Phase 2 clinical trial.
Commenting on the announced merger plans, Richard A. Franco, Sr., DARA's President and Chief Executive Officer, stated, "All parties involved believe this to be a logical and productive course of action given the potential synergies of combining Point and DARA. We believe this transaction provides an exciting opportunity for the stockholders of both companies to realize value and liquidity from this combination."
"We are excited about the opportunity to merge with DARA," said Don Kiepert, Point's Chairman and President. "The combination of Point and DARA will give our stockholders an opportunity to retain an equity interest in a stronger company with a broad and attractive portfolio of potential products."
Point and DARA believe that the proposed merger will qualify as a "reverse merger" under NASDAQ Marketplace Rule 4340. As a result, although Point's common stock is currently listed on NASDAQ, DARA intends to file an initial listing application and satisfy all requirements for initial listing, subject to the completion of the merger and NASDAQ approval. As previously announced on September 17, 2007, Point received a determination letter from the staff of The NASDAQ Stock Market indicating that Point's securities are subject to potential delisting from NASDAQ. The staff determination was based on the fact that Point does not currently meet the $1 minimum share price requirement for continued listing on NASDAQ and that Point's recent cessation of its clinical and research operations renders Point a "public shell," or non-operating company in the opinion of the staff. Point has requested a hearing before a NASDAQ Listing Qualifications Panel and intends to seek continued listing of its common stock pending the completion of the merger, subject to NASDAQ approval.
About Point Therapeutics, Inc.
Point Therapeutics, Inc. is a biopharmaceutical company which has studied its lead product candidate, talabostat, in a number of human clinical trials in late-stage cancers. Recent interim clinical results caused Point's Independent Data Monitoring Committee to recommend stopping Point's most advanced clinical trials, two Phase 3 talabostat studies for patients in advanced non-small cell lung cancer. Subsequently, the talabostat clinical development program was put on clinical hold by the FDA. Point has also studied talabostat in several Phase 2 trials, including as a single-agent and in combination with cisplatin in metastatic melanoma, in combination with rituximab in advanced chronic lymphocytic leukemia, and in combination with gemcitabine in Stage IV pancreatic cancer. Due to cash limitations, Point is not currently funding any research or clinical operations.
About DARA BioSciences, Inc.
DARA BioSciences(TM), Inc. is a Raleigh, North Carolina-based development-stage pharmaceutical company that acquires promising therapeutic molecules and medical technologies directly. DARA focuses its therapeutic development efforts on small molecules from late preclinical development through phase 2 clinical trials. DARA is developing a portfolio of therapeutic candidates for neuropathic pain, metabolic diseases including Type 2 diabetes, and dermatological disorders.
For more information, please contact DARA at 919-872-5578 or visit our web site at www.darabiosciences.com.
Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include receipt of stockholder and regulatory approvals and other risks that the transaction might not close, integration of the two companies, risks related to the potential lack of a liquid market for the company's stock, reliance on key employees, risks of testing of drug candidates for proof of principle, risks of regulatory review and clinical trials, competition, market acceptance for approved products, if any, and intellectual property risks.
Additional Information
In connection with the merger between DARA and Point, Point intends to file with the SEC a registration statement on Form S-4, containing a joint proxy statement/prospectus and other relevant materials. INVESTORS AND SECURITY HOLDERS OF DARA AND POINT ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND THE OTHER RELEVANT MATERIALS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT DARA, POINT AND THE MERGER. The joint proxy statement/prospectus and other relevant materials (when they become available), and any other documents filed by Point with the SEC, may be obtained free of charge at the SEC's web site at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents (when they are available) filed with the SEC by Point by directing a request to: Point Therapeutics, Inc., 70 Walnut Street, Wellesley Hills, MA 02481, Attention: Investor Relations.
Point and its executive officers and directors may be deemed to be participants in the solicitation of proxies from the stockholders of Point in favor of the merger. Information about the executive officers and directors of Point and their ownership of Point common stock is set forth in Point's Annual Report on Form 10-K/A filed with the SEC on April 30, 2007. Investors and stockholders may obtain more detailed information regarding the direct and indirect interests of DARA, Point and their respective executive officers and directors in the merger by reading the joint proxy statement/prospectus regarding the merger when it becomes available.
ihr seid doch jetzt alle reich oder?
Hab noch was anderes für euch.
HB2
Bin grad mal rein.
Total ausgebombt.
Gruß SGDfigther
HB2
Bin grad mal rein.
Total ausgebombt.
Gruß SGDfigther
Antwort auf Beitrag Nr.: 31.930.318 von aloevera2750 am 10.10.07 19:47:04Hatte Damenbesuch.Das hat sich bissl hingezogen.
Bin trotzdem mal rein.
Denke die geht heut noch mal hoch.
Bin trotzdem mal rein.
Denke die geht heut noch mal hoch.
Antwort auf Beitrag Nr.: 31.929.838 von aloevera2750 am 10.10.07 19:20:37ich glaube nicht
ich bin zu 0,40 rauß
ich bin zu 0,40 rauß
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 88 | ||
| 68 | ||
| 55 | ||
| 41 | ||
| 36 | ||
| 25 | ||
| 17 | ||
| 12 | ||
| 12 | ||
| 12 |
